Tourmaline Bio, Inc.
TRML · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $39 | $33 | $6 | $623 |
| Gross Profit | -$39 | -$33 | -$6 | -$623 |
| % Margin | – | – | – | – |
| R&D Expenses | $66,985 | $32,368 | $17,526 | $0 |
| G&A Expenses | $22,747 | $13,041 | $2,175 | $1 |
| SG&A Expenses | $22,747 | $13,041 | $2,175 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $46,883 |
| Operating Expenses | $89,732 | $45,409 | $19,701 | $46,884 |
| Operating Income | -$89,732 | -$45,409 | -$19,701 | -$47,507 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $16,522 | $3,285 | $0 | -$326 |
| Pre-Tax Income | -$73,210 | -$42,124 | -$19,701 | -$47,833 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$73,210 | -$42,124 | -$19,701 | -$1 |
| % Margin | – | – | – | – |
| EPS | -2.89 | -8.87 | -0.97 | -0 |
| % Growth | 67.4% | -814.4% | -969,900% | – |
| EPS Diluted | -2.89 | -8.87 | -0.97 | -0 |
| Weighted Avg Shares Out | 25,348 | 4,747 | 20,337 | 10,875 |
| Weighted Avg Shares Out Dil | 25,348 | 4,747 | 20,337 | 10,875 |
| Supplemental Information | – | – | – | – |
| Interest Income | $16,522 | $3,285 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $326 |
| Depreciation & Amortization | -$16,522 | $33 | $6 | $623 |
| EBITDA | -$89,732 | -$42,091 | -$19,695 | -$46,884 |
| % Margin | – | – | – | – |